Tiako Meyo et al. found that increased (> 30%) or stable levels of sPD-1 after two cycles of nivolumab in NSCLC patients correlated with both longer PFS (median: 121 vs 50 days) and OS (median: 450 vs 153 days) [77]. The gene discussed is HOXD13; the disease is non-small cell lung carcinoma.